AMI urged multinational drugmakers to do more to ensure that their suppliers of bulk antibiotic ingredients were complying with rigorous wastewater standards. Photo: Pradeep Gaur/MintLondon: Drugmakers’ response to the threat posed by “superbugs” remains patchy even after years of warnings, according to the first analysis of individual companies’ efforts to tackle the antibiotic resistance crisis. “There’s definitely more that all companies can do,” said Jayasree Iyer, executive director of AMI, which published the analysis at the World Economic Forum (WEF) annual meeting in Davos. Another under-recognised problem is the pollution caused by mass production of antibiotics, due to lax oversight of wastewater run-off. The AMI urged multinational drugmakers to do more to ensure that their suppliers of bulk antibiotic ingredients were complying with rigorous wastewater standards.

Source: Mint January 23, 2018 15:00 UTC